International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(8), P. 3858 - 3858
Published: April 18, 2025
Diagnosing
traumatic
brain
injury
(TBI)
remains
challenging
due
to
an
incomplete
understanding
of
its
neuropathological
mechanisms.
TBI
is
recognised
as
a
complex
condition
involving
both
primary
and
secondary
injuries.
Although
oxidative
stress
non-specific
molecular
phenomenon
observed
in
various
conditions,
it
plays
crucial
role
response
recovery.
Due
these
aspects,
we
aimed
evaluate
the
interaction
between
some
known
biomarkers
providing
evidence
for
possible
relevance
clinical
diagnosis
outcome
prediction.
We
found
that
while
many
currently
validated
interact
with
pathways,
their
patterns
variation
could
assist
diagnosis,
prognosis,
outcomes
prediction
cases.
Clinical Chemistry and Laboratory Medicine (CCLM),
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 7, 2025
Abstract
Objectives
To
assess
the
analytical
performances
of
Snibe
Maglumi
®
S100
assay
and
compare
it
with
Roche
Elecsys
S100B
in
adults
mild
traumatic
brain
injury
(mTBI)
focusing
on
reducing
unnecessary
cranial
computed
tomography
(CT)
scans
per
Scandinavian
French
guidelines.
Methods
Analytical
performance
kit
was
assessed
using
quality
controls
from
both
Roche,
as
well
pooled
serums.
Clinical
were
serum
89
adult
mTBI
patients
presenting
to
emergency
department
Clermont-Ferrand
University
Hospital
a
Glasgow
Coma
Scale
score
14–15.
CT
performed
according
measurement,
decision
threshold
0.10
μg/L.
Results
Repeatability
reproducibility
coefficients
variation
determined
S100B,
serums
below
8
%.
Six
(7
%)
included
had
clinically
relevant
intracranial
lesions
observed
scan
(CT+),
eighty-three
(93
no
(CT-).
medians
CT-
CT+
significantly
different:
0.125
(0.085–0.219)
vs.
0.368
(0.231–0.489)
(p=0.006)
for
,
0.073
(0.046–0.140)
0.327
(0.230–0.353)
(p=0.004).
The
areas
under
ROC
curves
lesion
detection
similar:
0.82
(0.73–0.91;
p=0.0084)
0.83
(0.75–0.92;
p=0.0063)
respectively.
Conclusions
can
be
used
management
exclude
scans.
Further
studies
are
needed
validate
clinical
decisions.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: Feb. 17, 2025
The
sampling
of
S100B
protein
has
been
proposed
as
a
screening
tool
to
identify
patients
with
low
risk
post-traumatic
intracranial
hemorrhage.
Its
performance
for
on
antiplatelet
agents
or
anticoagulants
is
still
debatable.
This
exploratory
study
evaluates
the
diagnostic
accuracy
concentrations,
measured
within
3
h
head
trauma,
rule
out
hemorrhage
in
adults
anticoagulant
therapy.
prospective
enrolled
adult
presenting
trauma
last
and
under
antiplatelets
anticoagulants.
We
hypothesized
that
concentration
0,100
µg.L-1
negative
predictive
value
over
0,99.
Sensitivity,
specificity,
positive
were
analyzed.
From
June
2020
January
2023,
155
included.
119
had
level
at
over.
8
an
sensitivity
was
1
(95%CI
0,68-1),
specificity
0,25
0,18
-
0,32),
0,07
0.03-0.13),
0,90
1).
suggests
when
performed
3-hour
period
after
mild
measurement
accurate
treated
Scandinavian Journal of Trauma Resuscitation and Emergency Medicine,
Journal Year:
2025,
Volume and Issue:
33(1)
Published: March 25, 2025
Abstract
Background
Few
countries
recommend
glial
fibrillary
protein
(GFAP)
and
ubiquitin
C-terminal
hydrolase-L1
(UCH-L1)
as
a
substitute
for
S100
astroglial
calcium-binding
B
(S100B)
in
early
detection
of
traumatic
intracranial
lesions
mild
TBI
(mTBI).
This
study
aims
to
evaluate
the
classification
agreement
between
S100B
GFAP/UCH-L1
Scandinavian
trauma
cohort,
performance
characteristics
lesions,
lastly
laboratory
assay.
Methods
Prospectively
collected
data
from
an
unselected
cohort
379
adult
patients
admitted
level
I
center
at
Aarhus
University
Hospital,
Denmark,
were
retrospectively
analyzed.
Analyses
performed
sub-cohort
1
(n
=
218)
i.e.
with
any
evidence
their
chart
well
2
105)
mTBI
defined
Glasgow
Coma
Scale
score
≥
14,
injury
severity
≤
15,
blood
sampling
within
6
h
or
12
after
trauma.
Plasma-samples
used
measurement
serum-samples
measurement.
Data
analysis
involved
using
Cohens
kappa
sensitivity,
specificity,
positive
predictive
value
negative
each
biomarker
three
cohorts.
Lastly,
levels
measured
by
Alinity-I
platform
Simoa
compared.
Results
Classification
was
high
all
cohorts,
but
improved
increasing
proximity
clinical
use
reached
almost
perfect
identity
(0.70,
95%
CI
0.62–0.92).
S100b
had
sensitivity
100%
2,
while
across
The
specificities
both
relatively
low.
Comparing
platforms
revealed
low
concordance
measuring
GFAP
on
average
65%
lower
UCH-L1
84%
higher
than
platform.
Conclusions
In
this
study,
comparable
diagnostic
performances
detecting
lesions.
Our
results
therefore
support
feasible
alternative
mTBI.
Journal of Neuroscience Research,
Journal Year:
2025,
Volume and Issue:
103(4)
Published: April 1, 2025
Mild
traumatic
brain
injury
(mTBI)
is
a
common
condition,
particularly
pervasive
in
contact
sports
environments.
A
range
of
symptoms
can
accompany
this
type
and
negatively
impact
people's
lives.
As
mTBI
diagnosis
recovery
largely
rely
on
subjective
reports,
more
objective
markers
are
needed.
The
current
study
compared
structural
MRI-T2
relaxometry
between
group
40
male
athletes
with
within
14
days
age-matched
controls.
Voxel-averaged
T2
the
gray
matter
was
increased
for
to
controls
(p
<
0.001),
statistically
significant
superior
cortical
regions.
Our
findings
indicate
subtle
abnormalities
be
identified
acute
using
relaxometry.
These
may
reflect
inflammation
present
could
constitute
an
marker
supplement
methods
that
dominate
clinical
decisions
regarding
prognosis.
Future
research
should
validate
potential
other
data
types,
such
as
blood
biomarkers
or
histological
samples.
Frontiers in Neuroscience,
Journal Year:
2025,
Volume and Issue:
19
Published: April 15, 2025
Traumatic
Brain
Injury
(TBI)
in
children
is
a
profound
public
health
issue
with
the
potential
to
disrupt
cognitive,
behavioral,
and
psychosocial
development
significantly.
This
review
provides
an
updated
examination
of
role
neuroinflammation
pediatric
TBI,
emphasizing
its
dual
impact
on
injury
progression
recovery.
Highlighted
complex
interplay
primary
secondary
mechanisms,
including
critical
contributions
neuroinflammatory
responses
mediated
by
central
peripheral
immune
cells.
Advances
biomarker
identification
imaging
techniques
are
discussed,
showcasing
how
tools
like
diffusion
tensor
(DTI)
positron
emission
tomography
(PET)
enhance
our
understanding
processes.
The
also
explores
current
therapeutic
strategies
targeting
neuroinflammation,
underscoring
emerging
treatments
such
as
pharmacologic
agents
that
modulate
novel
therapies
stem
cell
interventions.
comprehensive
seeks
deepen
neuroinflammation’s
pathophysiological
roles
TBI
propose
directions
for
future
clinical
research
efforts.
